Wanfang Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Wanfang Zhang has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
Suzanne McDermott
Department of Environmental, Occupational, and Geospatial Health Sciences, Graduate School of Public Health & Health Policy City University of New York New York New York USA
3 shared publicationsChristina Westfield
Division of Population Health Surveillance, Department of Health Bureau of Maternal and Child Health Columbia South Carolina USA
2 shared publications- Nicholas E. Johnson
Department of Neurology, Virginia Commonwealth University, Richmond
2 shared publications Abigail Lyons
Department of Environmental, Occupational, and Geospatial Health Sciences, Graduate School of Public Health & Health Policy City University of New York New York New York USA
1 shared publicationAida Soim
New York State Department of Health Albany New York USA
1 shared publicationAmy Moore
RTI International Research Triangle Park North Carolina USA
1 shared publication
Latest Publications
- 29 September 2025
- Published by Wiley in Muscle & Nerve
- Vol. 72 (6) , 1317-1318
Reply to: “Beyond Prevalence: The Importance of Multifactorial Assessment in Cancer Risk Among Myotonic Dystrophy Patients”
- 29 September 2025
- Published by Wiley in Muscle & Nerve
- Vol. 72 (6) , 1317-1318
Reply to: “Beyond Prevalence: The Importance of Multifactorial Assessment in Cancer Risk Among Myotonic Dystrophy Patients”
- 30 June 2025
- Published by Wiley in Muscle & Nerve
- Vol. 72 (4) , 570-579
Elevated Cancer Prevalence Identified at Specific Anatomical Sites Among People With Myotonic Dystrophy Using a Population‐Based Sample
Introduction/Aim: To optimize patient care and cancer screening in myotonic dystrophy (DM), it is crucial to clarify cancer risks by DM type to guide targeted screening and prevention efforts. This study describes the prevalence of cancer among individuals diagnosed with DM from the Muscular Dystrophy Surveillance, Tracking, and Research Network (MD STARnet), and compares it to cancer prevalence in the US Surveillance, Epidemiology, and End Result (SEER) data.Methods: This retrospective cohort study used 2008–2019 medical records data on 1229 individuals diagnosed with DM (DM1: 81.4%, DM2: 9.4%, DM‐not otherwise specified [NOS]: 9.2%) from MD STARnet. Age‐ and sex‐specific cancer prevalence rates from SEER were applied to the MD STARnet data to calculate 12‐year limited duration (LD) and complete standardized prevalence ratios (SPR) for total cancer and by primary cancer site.Results: Over a 12‐year span, individuals with DM1 had a 4.01‐fold higher LD prevalence of thyroid cancer and a 17.97‐fold higher LD prevalence of nonmelanoma skin cancer compared to the SEER prevalence, respectively. Complete prevalence assessments identified that individuals with DM1 had a 4.18‐fold higher prevalence of thyroid cancer, a 2.36‐fold higher prevalence of melanoma, and a 4.68‐fold higher prevalence of ovarian cancer. For DM2, the study observed a 34.02‐fold higher LD prevalence for nonmelanoma skin cancer. Additionally, a significantly elevated complete prevalence of breast cancer (2.65‐fold) was noted for DM2 compared to SEER data.Discussion: Future research with larger cohorts is needed to define cancer risks by DM subtype and investigate underlying biological mechanisms.
- 30 June 2025
- Published by Wiley in Muscle & Nerve
- Vol. 72 (4) , 570-579
Elevated Cancer Prevalence Identified at Specific Anatomical Sites Among People With Myotonic Dystrophy Using a Population‐Based Sample
Introduction/Aim: To optimize patient care and cancer screening in myotonic dystrophy (DM), it is crucial to clarify cancer risks by DM type to guide targeted screening and prevention efforts. This study describes the prevalence of cancer among individuals diagnosed with DM from the Muscular Dystrophy Surveillance, Tracking, and Research Network (MD STARnet), and compares it to cancer prevalence in the US Surveillance, Epidemiology, and End Result (SEER) data.Methods: This retrospective cohort study used 2008–2019 medical records data on 1229 individuals diagnosed with DM (DM1: 81.4%, DM2: 9.4%, DM‐not otherwise specified [NOS]: 9.2%) from MD STARnet. Age‐ and sex‐specific cancer prevalence rates from SEER were applied to the MD STARnet data to calculate 12‐year limited duration (LD) and complete standardized prevalence ratios (SPR) for total cancer and by primary cancer site.Results: Over a 12‐year span, individuals with DM1 had a 4.01‐fold higher LD prevalence of thyroid cancer and a 17.97‐fold higher LD prevalence of nonmelanoma skin cancer compared to the SEER prevalence, respectively. Complete prevalence assessments identified that individuals with DM1 had a 4.18‐fold higher prevalence of thyroid cancer, a 2.36‐fold higher prevalence of melanoma, and a 4.68‐fold higher prevalence of ovarian cancer. For DM2, the study observed a 34.02‐fold higher LD prevalence for nonmelanoma skin cancer. Additionally, a significantly elevated complete prevalence of breast cancer (2.65‐fold) was noted for DM2 compared to SEER data.Discussion: Future research with larger cohorts is needed to define cancer risks by DM subtype and investigate underlying biological mechanisms.
- Open Access
- 1 December 2023
- Published by Wolters Kluwer Health in Neurology Genetics
- Vol. 9 (6) , e200113
Genetic Patterns of Selected Muscular Dystrophies in the Muscular Dystrophy Surveillance, Tracking, and Research Network
Background and Objectives To report the genetic etiologies of Emery-Dreifuss muscular dystrophy (EDMD), limb-girdle muscular dystrophy (LGMD), congenital muscular dystrophy (CMD), and distal muscular dystrophy (DD) in 6 geographically defined areas of the United States. Methods This was a cross-sectional, population-based study in which we studied the genes and variants associated with muscular dystrophy in individuals who were diagnosed with and received care for EDMD, LGMD, CMD, and DD from January 1, 2008, through December 31, 2016, in the 6 areas of the United States covered by the Muscular Dystrophy Surveillance, Tracking, and Research Network (MD STARnet). Variants of unknown significance (VUSs) from the original genetic test reports were reanalyzed for changes in interpretation. Results Among 243 individuals with definite or probable muscular dystrophy, LGMD was the most common diagnosis (138 cases), followed by CMD (62 cases), DD (22 cases), and EDMD (21 cases). There was a higher proportion of male individuals compared with female individuals, which persisted after excluding X-linked genes (EMD) and autosomal genes reported to have skewed gender ratios (ANO5, CAV3, and LMNA). The most common associated genes were FKRP, CAPN3, ANO5, and DYSF. Reanalysis yielded more definitive variant interpretations for 60 of 144 VUSs, with a mean interval between the original clinical genetic test of 8.11 years for all 144 VUSs and 8.62 years for the 60 reclassified variants. Ten individuals were found to have monoallelic pathogenic variants in genes known to be primarily recessive. Discussion This study is distinct for being an examination of 4 types of muscular dystrophies in selected geographic areas of the United States. The striking proportion of resolved VUSs demonstrates the value of periodic re-examinations of these variants. Such re-examinations will resolve some genetic diagnostic ambiguities before initiating repeat testing or more invasive diagnostic procedures such as muscle biopsy. The presence of monoallelic pathogenic variants in recessive genes in our cohort indicates that some individuals with muscular dystrophy continue to face incomplete genetic diagnoses; further refinements in genetic knowledge and diagnostic approaches will optimize diagnostic information for these individuals.
- 1 December 2023
- Published by Wolters Kluwer Health in Neurology Genetics
- Vol. 9 (6) , e200113
Open AccessGenetic Patterns of Selected Muscular Dystrophies in the Muscular Dystrophy Surveillance, Tracking, and Research Network
Background and Objectives To report the genetic etiologies of Emery-Dreifuss muscular dystrophy (EDMD), limb-girdle muscular dystrophy (LGMD), congenital muscular dystrophy (CMD), and distal muscular dystrophy (DD) in 6 geographically defined areas of the United States. Methods This was a cross-sectional, population-based study in which we studied the genes and variants associated with muscular dystrophy in individuals who were diagnosed with and received care for EDMD, LGMD, CMD, and DD from January 1, 2008, through December 31, 2016, in the 6 areas of the United States covered by the Muscular Dystrophy Surveillance, Tracking, and Research Network (MD STARnet). Variants of unknown significance (VUSs) from the original genetic test reports were reanalyzed for changes in interpretation. Results Among 243 individuals with definite or probable muscular dystrophy, LGMD was the most common diagnosis (138 cases), followed by CMD (62 cases), DD (22 cases), and EDMD (21 cases). There was a higher proportion of male individuals compared with female individuals, which persisted after excluding X-linked genes (EMD) and autosomal genes reported to have skewed gender ratios (ANO5, CAV3, and LMNA). The most common associated genes were FKRP, CAPN3, ANO5, and DYSF. Reanalysis yielded more definitive variant interpretations for 60 of 144 VUSs, with a mean interval between the original clinical genetic test of 8.11 years for all 144 VUSs and 8.62 years for the 60 reclassified variants. Ten individuals were found to have monoallelic pathogenic variants in genes known to be primarily recessive. Discussion This study is distinct for being an examination of 4 types of muscular dystrophies in selected geographic areas of the United States. The striking proportion of resolved VUSs demonstrates the value of periodic re-examinations of these variants. Such re-examinations will resolve some genetic diagnostic ambiguities before initiating repeat testing or more invasive diagnostic procedures such as muscle biopsy. The presence of monoallelic pathogenic variants in recessive genes in our cohort indicates that some individuals with muscular dystrophy continue to face incomplete genetic diagnoses; further refinements in genetic knowledge and diagnostic approaches will optimize diagnostic information for these individuals.
- Open Access
- 4 October 2021
- Published by Elsevier in Disability and Health Journal
- Vol. 15 (1) , 101219
Helpers help people with intellectual and developmental disabilities and hypertension to understand their condition and the need to adhere to anti-hypertensive medication
- 4 October 2021
- Published by Elsevier in Disability and Health Journal
- Vol. 15 (1) , 101219
Open AccessHelpers help people with intellectual and developmental disabilities and hypertension to understand their condition and the need to adhere to anti-hypertensive medication